Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus
Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus
复制标题
DOI：
10.1038/clpt.2011.16
复制
发表时间：
2011-04-01
影响因子：
6.7
通讯作者：
List, J. F.
中科院分区：
文献类型：
--
作者：
Pfister, M.;Whaley, J. M.;List, J. F.
钠-葡萄糖协同转运蛋白2（SGLT 2）的选择性抑制最近已成为潜在的2型糖尿病（T2 DM）治疗的焦点。本文综述了SGLT 2诱导尿糖排泄（UGE）的机制及其对动物模型、健康人和T2 DM患者血糖控制参数的影响。讨论了SGLT 2抑制剂开发各个方面的关键问题，以及有关该领域的见解。
The selective inhibition of sodium-glucose cotransporter 2 (SGLT2) has recently become a focus of potential type 2 diabetes mellitus (T2DM) therapeutics. This review describes the mechanism of SGLT2-induced urinary glucose excretion (UGE) and its effects on parameters of glycemic control in animal models, healthy humans, and patients with T2DM. Key questions on various aspects of the development of SGLT2 inhibitors are discussed, as well as insights regarding this field.